Qualigen Therapeutics, Inc. received a notice from Nasdaq on July 23, 2025, indicating non-compliance with the $2.5 million stockholders’ equity requirement, but secured a compliance extension due to a recent $4.5 million funding. The company has submitted a plan to regain compliance over the next year.